Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
Stage IV or recurrent disease
Measurable disease
Disease progression or recurrence during or after completion of prior first-line chemotherapy with fluorouracil and leucovorin calcium (5-FU/LV)
Prior irinotecan or oxaliplatin as part of the 5-FU/LV regimen or as subsequent therapy allowed
Only 2 prior regimens for metastatic disease allowed
One additional regimen as adjuvant therapy allowed provided patient remained disease-free for \> 6 months after completion of therapy\*
Newer, targeted investigational agents (e.g., cetuximab or bevacizumab) are not
counted as a chemotherapeutic regimen unless used in combination with a cytotoxic regimen NOTE: \*If evidence of failure occurred within \< 6 months after completion of adjuvant therapy, patients may have received only 1 additional regimen for metastatic disease
No active brain metastases (requiring treatment or progressing)
You may not be if
History of blood transfusion within 14 days
Need of concurrent Administration of allopurinol
History of Radiotherapy or Chemotherapy within 4 weeks
Any psychological or sociological condition, addidtive disorder or family problems that might preclude compliance with the protocol
Any unstable or severe intercurrent medical condition that in the opinion of th einvestigator might interfere with achievement of study objectives
Receipt of an investigational agent within 28 days prior to first day of dosing with AG-2037
Pregnant or breast feeding
Previous treatment with GARFT inhibitors
History of a malignancy (other than colorectal cancer) excpet those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years
Active brain metastases (requiring treatment or progression)
Clareo Health | Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
